|
Jun 24
|
Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
|
|
Jun 20
|
Roche launches B-cell lymphoma diagnostic assay in Europe
|
|
Jun 20
|
Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
|
|
Jun 19
|
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
|
|
Jun 19
|
Ascidian and Roche to develop RNA therapies for neurological diseases
|
|
Jun 18
|
Roche gains 501(k) clearance for digital pathology solution for diagnostic use
|
|
Jun 18
|
Roche partners with RNA editing biotech Ascidian
|
|
Jun 18
|
Roche receives FDA clearance on its digital pathology solution for diagnostic use
|
|
Jun 17
|
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
|
|
Jun 17
|
Roche’s Columvi offers extended survival in Phase III DLBCL trial
|
|
Jun 17
|
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
|
|
Jun 15
|
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
|
|
Jun 15
|
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
May 24
|
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
|
|
May 22
|
Roche’s Tina-quant Lp(a) test receives FDA breakthrough device designation
|
|
May 22
|
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
|
|
May 21
|
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
|
|
May 21
|
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
|
|
May 21
|
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
May 20
|
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
|